Prognostic value of real-time quantitative PCR (RQ-PCR) in AML with t(8;21).
about
Minimal Residual Disease in Acute Myeloid Leukemia of Adults: Determination, Prognostic Impact and Clinical ApplicationsMinimal Residual Disease in Acute Myeloid Leukemia: Still a Work in Progress?Core-binding factor acute myeloid leukemia: Heterogeneity, monitoring, and therapy.Molecular diagnostics in acute leukemias.High expression of c-kit mRNA predicts unfavorable outcome in adult patients with t(8;21) acute myeloid leukemia.Comparative analysis of different approaches to measure treatment response in acute myeloid leukemiaProspective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial.Identification and characterization of novel AML1-ETO fusion transcripts in pediatric t(8;21) acute myeloid leukemia: a report from the Children's Oncology Group.Supraphysiologic levels of the AML1-ETO isoform AE9a are essential for transformation.Multiplexed automated digital quantification of fusion transcripts: comparative study with fluorescent in-situ hybridization (FISH) technique in acute leukemia patients.Interactive diagnostics in the indication to allogeneic SCT in AML.Minimal residual disease quantitation in acute myeloid leukemiaThe dynamics of RUNX1-RUNX1T1 transcript levels after allogeneic hematopoietic stem cell transplantation predict relapse in patients with t(8;21) acute myeloid leukemia.Pathways involved in Drosophila and human cancer development: the Notch, Hedgehog, Wingless, Runt, and Trithorax pathway.Perspective on how to approach molecular diagnostics in acute myeloid leukemia and myelodysplastic syndromes in the era of next-generation sequencing.Relapse assessment following allogeneic SCT in patients with MDS and AML.Prognosis and monitoring of core-binding factor acute myeloid leukemia: current and emerging factors.Minimal residual disease in acute myeloid leukemia--current status and future perspectives.Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia.Clinical Relevance of RUNX1 and CBFB Alterations in Acute Myeloid Leukemia and Other Hematological Disorders.Peripheral blood minimal residual disease may replace bone marrow minimal residual disease as an immunophenotypic biomarker for impending relapse in acute myeloid leukemia.Minimal Residual Disease in Acute Myeloid Leukemia.Preventing relapse after haematopoietic stem cell transplantation for acute leukaemia: the role of post-transplantation minimal residual disease (MRD) monitoring and MRD-directed intervention.The quality of molecular response to chemotherapy is predictive for the outcome of AML1-ETO-positive AML and is independent of pretreatment risk factors.The impact of pre-transplant minimal residual disease on outcome of intensified myeloablative cord blood transplant for acute myeloid leukemia in first or second complete remission.Acute myeloid leukemia with the t(8;21) translocation: clinical consequences and biological implications.Slow relapse in acute myeloid leukemia with inv(16) or t(16;16).Monitoring of minimal residual disease in acute myeloid leukemia with t(8;21)(q22;q22).Amyloid precursor protein has clinical and prognostic significance in AML1-ETO-positive acute myeloid leukemia.Comparison of Multiparameter Flow Cytometry Immunophenotypic Analysis and Quantitative RT-PCR for the Detection of Minimal Residual Disease of Core Binding Factor Acute Myeloid Leukemia.Monitoring the AML1/ETO fusion transcript to predict outcome in childhood acute myeloid leukemia.A >or=1 log rise in RQ-PCR transcript levels defines molecular relapse in core binding factor acute myeloid leukemia and predicts subsequent morphologic relapse.Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)].Quantification of CBFB-MYH11 fusion gene levels in paired peripheral blood and bone marrow samples by real-time PCR.Monitoring of minimal residual disease in patients with core binding factor acute myeloid leukemia and the impact of C-KIT, FLT3, and JAK2 mutations on clinical outcome.
P2860
Q28073464-298CE6E8-FD05-4B34-989A-3ED40EA5DBA6Q33832709-019B35B0-DD67-4C0B-9B1B-661E5F6115FFQ34663691-3F0CE17D-DF21-4F27-A968-6EFEFEA30005Q35007333-BF6CCC95-5B09-412F-8B1C-D39482CB9BA1Q35361598-6F6D130C-F3D2-4386-929C-C8C1ECB2DB25Q36290737-F7028BA3-3A66-4B0B-B058-AA760D4D086AQ36750458-6B169282-180C-4B1D-93F8-26388B84F432Q37149438-242BB9D7-465A-4D9C-BB33-F513419A1E1EQ37181755-84DE0D84-5FBB-4139-A719-BD9DB1FAFBCFQ37258116-CBF48BBC-788F-4348-9EFB-23FA9FC67BA7Q37442649-A5F3C69A-10D5-42E8-88D1-78CF03AD2772Q37447344-B9293EBB-B367-4F9C-9305-F20335F86C41Q37628021-FB6D4941-747B-4EE4-A3E0-0B1BF4B0D550Q37993742-6523571B-6B11-4089-A1B0-CB0C909AC4BBQ38154339-1363B5E2-76D2-4E31-A94E-B3E4CA1C87DBQ38199623-D8053712-8131-43D7-8ECB-D5B37CC6538AQ38263126-D16EA066-6AB6-4E3F-8BCE-9CF42110B960Q38494659-445E05AF-76E4-405E-BDDF-62A658DDF73DQ38791735-DEBF4257-F0E6-4C8F-9414-053A89251B54Q38904250-48F19F00-715C-42B3-B187-AC93EF91A4C3Q38963613-77B62BD1-CD07-4281-BEF7-75C07CEFA715Q39097771-63AE94F9-6C8A-4437-AE03-6C2623215BC6Q39329093-FE3A46BF-9615-46F5-A380-4812395E0C17Q40231262-6614CB42-BEC0-42F9-92A4-7A887A892A4DQ41032064-F99E6AF5-9B8F-4D72-8A4A-D8FA76830511Q41973082-625E2B73-D19F-407C-87D9-C5E76F6E13BCQ42574037-FE46D84B-B206-4EE1-A836-7F841BEBAF7DQ46770525-90B71822-3FBA-44AF-99C0-0581F3D3D555Q49335168-3986A468-43A6-4AE5-89A4-2041F36DF138Q51704129-F8E93505-67C4-44A6-BB69-CB133DF99CC7Q54203721-2A3479A3-B4EC-407C-8397-682C09294CC7Q54545134-60383CBA-CF9C-42AD-99AC-9A691556213EQ54631878-CB881506-74B2-4EC4-8BCA-C6D5D71FDD49Q54639524-10C9B28B-FA22-4F69-BF6A-C53295F3A0EDQ54732689-182DEF24-7AC3-473A-B5C2-597FAFAD57A4
P2860
Prognostic value of real-time quantitative PCR (RQ-PCR) in AML with t(8;21).
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Prognostic value of real-time quantitative PCR (RQ-PCR) in AML with t(8;21).
@en
type
label
Prognostic value of real-time quantitative PCR (RQ-PCR) in AML with t(8;21).
@en
prefLabel
Prognostic value of real-time quantitative PCR (RQ-PCR) in AML with t(8;21).
@en
P2093
P2860
P356
P1433
P1476
Prognostic value of real-time quantitative PCR (RQ-PCR) in AML with t(8;21).
@en
P2093
Grardel-Duflos N
Morschhauser F
Preudhomme C
P2860
P2888
P304
P356
10.1038/SJ.LEU.2403627
P577
2005-03-01T00:00:00Z
P5875
P6179
1005122554